Quince Therapeutics Files Routine 8-K on Jan 23 Event
Ticker: QNCX · Form: 8-K · Filed: Jan 29, 2024 · CIK: 1662774
| Field | Detail |
|---|---|
| Company | Quince Therapeutics, Inc. (QNCX) |
| Form Type | 8-K |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, routine-filing
TL;DR
**Quince Therapeutics filed a routine 8-K, nothing major to see here.**
AI Summary
Quince Therapeutics, Inc. filed an 8-K on January 29, 2024, reporting an event that occurred on January 23, 2024. This filing is a standard current report, indicating no major changes in the company's structure or operations beyond routine disclosures. For investors, this filing suggests business as usual, with no immediate red flags or significant positive catalysts, meaning the stock's value is unlikely to be directly impacted by this specific report.
Why It Matters
This filing is a standard disclosure and does not contain information that would typically cause a significant immediate change in the stock price or investor sentiment.
Risk Assessment
Risk Level: low — The filing is a standard current report with no specific details indicating new risks or changes to existing risks.
Analyst Insight
Given the routine nature of this 8-K filing, a smart investor would not make any immediate trading decisions based solely on this report. It's important to monitor future filings for more substantive news.
Key Players & Entities
- Quince Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 23, 2024 (date) — date of the earliest event reported in the 8-K
- January 29, 2024 (date) — date the 8-K was filed
FAQ
What is the purpose of this 8-K filing by Quince Therapeutics, Inc.?
This 8-K filing is a 'Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934' by Quince Therapeutics, Inc., reporting an event that occurred on January 23, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 23, 2024, as stated in the 'Date of Report (Date of earliest event reported)' section.
What is the full legal name of the company filing this 8-K?
The exact name of the registrant as specified in its charter is QUINCE THERAPEUTICS, INC.
What is Quince Therapeutics, Inc.'s business address?
Quince Therapeutics, Inc.'s principal executive offices are located at 611 Gateway Boulevard, Suite 273, South San Francisco, California, 94080.
Does this 8-K filing indicate any simultaneous satisfaction of other filing obligations?
No, the checkboxes for 'Written communications pursuant to Rule 425', 'Soliciting material pursuant to Rule 14a-12', 'Pre-commencement communications pursuant to Rule 14d-2(b)', and 'Pre-commencement communications pursuant to Rule 13e-4(c)' are all unchecked, indicating this filing is not intended to simultaneously satisfy those obligations.
Filing Stats: 607 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2024-01-29 16:00:58
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share QNCX Nasdaq Global Select
Filing Documents
- d661573d8k.htm (8-K) — 30KB
- 0001193125-24-018071.txt ( ) — 185KB
- qncx-20240123.xsd (EX-101.SCH) — 4KB
- qncx-20240123_def.xml (EX-101.DEF) — 13KB
- qncx-20240123_lab.xml (EX-101.LAB) — 22KB
- qncx-20240123_pre.xml (EX-101.PRE) — 14KB
- d661573d8k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Quince Therapeutics, Inc. Date: January 29, 2024 By: /s/ Dirk Thye Name: Dirk Thye Title: Chief Executive Officer